410 related articles for article (PubMed ID: 22711238)
21. Busulfan dosing in children with BMIs ≥ 85% undergoing HSCT: a new optimal strategy.
Browning B; Thormann K; Donaldson A; Halverson T; Shinkle M; Kletzel M
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1383-8. PubMed ID: 21288495
[TBL] [Abstract][Full Text] [Related]
22. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment.
Lalonde RL; Wagner JA
Clin Pharmacol Ther; 2009 Nov; 86(5):557-61. PubMed ID: 19776736
[TBL] [Abstract][Full Text] [Related]
23. Drug therapy in childhood: what has been done and what has to be done?
Bartels H
Pediatr Pharmacol (New York); 1983; 3(3-4):131-43. PubMed ID: 6677868
[TBL] [Abstract][Full Text] [Related]
24. A model-based approach to dose selection in early pediatric development.
Cella M; Gorter de Vries F; Burger D; Danhof M; Della Pasqua O
Clin Pharmacol Ther; 2010 Mar; 87(3):294-302. PubMed ID: 20107435
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic- and pharmacodynamic-based antithrombotic dosing recommendations in children.
Ko RH; Young G
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):389-96. PubMed ID: 22943118
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial dosing considerations in obese adult patients.
Pai MP; Bearden DT
Pharmacotherapy; 2007 Aug; 27(8):1081-91. PubMed ID: 17655508
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling.
Bouzom F; Walther B
Fundam Clin Pharmacol; 2008 Dec; 22(6):579-87. PubMed ID: 19049658
[TBL] [Abstract][Full Text] [Related]
28. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
[TBL] [Abstract][Full Text] [Related]
29. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.
McLeay SC; Morrish GA; Kirkpatrick CM; Green B
Clin Pharmacokinet; 2012 May; 51(5):319-30. PubMed ID: 22439649
[TBL] [Abstract][Full Text] [Related]
30. Lean-scaled weight: a proposed weight scalar to calculate drug doses for obese patients.
Friesen JH
Can J Anaesth; 2013 Feb; 60(2):214-5. PubMed ID: 23192695
[No Abstract] [Full Text] [Related]
31. Drug disposition in obesity: toward evidence-based dosing.
Knibbe CA; Brill MJ; van Rongen A; Diepstraten J; van der Graaf PH; Danhof M
Annu Rev Pharmacol Toxicol; 2015; 55():149-67. PubMed ID: 25340929
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of high-dose carboplatin in children and adults.
Lindauer A; Eickhoff C; Kloft C; Jaehde U
Ther Drug Monit; 2010 Apr; 32(2):159-68. PubMed ID: 20110851
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Sparreboom A; Wolff AC; Mathijssen RH; Chatelut E; Rowinsky EK; Verweij J; Baker SD
J Clin Oncol; 2007 Oct; 25(30):4707-13. PubMed ID: 17947717
[TBL] [Abstract][Full Text] [Related]
34. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature.
Myzienski AE; Lutz MF; Smythe MA
Pharmacotherapy; 2010 Mar; 30(3):324. PubMed ID: 20180615
[TBL] [Abstract][Full Text] [Related]
35. [Drug dosing in overweight and underweight].
Raknes G; Schjøtt JD
Tidsskr Nor Laegeforen; 2008 Aug; 128(16):1843-4. PubMed ID: 18787597
[No Abstract] [Full Text] [Related]
36. Anesthesia in the obese patient: pharmacokinetic considerations.
Casati A; Putzu M
J Clin Anesth; 2005 Mar; 17(2):134-45. PubMed ID: 15809132
[TBL] [Abstract][Full Text] [Related]
37. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
Schmitt A; Gladieff L; Lansiaux A; Bobin-Dubigeon C; Etienne-Grimaldi MC; Boisdron-Celle M; Serre-Debauvais F; Pinguet F; Floquet A; Billaud E; Le Guellec C; Penel N; Campone M; Largillier R; Capitain O; Fabbro M; Houede N; Medioni J; Bougnoux P; Lochon I; Chatelut E
Clin Cancer Res; 2009 May; 15(10):3633-9. PubMed ID: 19401344
[TBL] [Abstract][Full Text] [Related]
38. Effects of tumor type, degree of obesity, and chemotherapy regimen on chemotherapy dose intensity in obese cancer patients.
Miyahara T; Mochinaga S; Kimura S; Aragane N; Yakabe T; Morita S; Okudaira K; Fujito H
Cancer Chemother Pharmacol; 2013 Jan; 71(1):175-82. PubMed ID: 23064956
[TBL] [Abstract][Full Text] [Related]
39. What is the best size descriptor to use for pharmacokinetic studies in the obese?
Green B; Duffull SB
Br J Clin Pharmacol; 2004 Aug; 58(2):119-33. PubMed ID: 15255794
[TBL] [Abstract][Full Text] [Related]
40. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
